Regarding the clinical presentation and management of atopic dermatitis in a 4-year-old Indian child, all of the following statements are correct EXCEPT:

Explanation

## Management Approach to Atopic Dermatitis in Children **Key Point:** Systemic corticosteroids are **NOT** first-line for AD and should be avoided as maintenance therapy due to risk of rebound flares, HPA axis suppression, and long-term adverse effects. They may be used briefly for acute exacerbations only. ### Stepwise Management Algorithm ```mermaid flowchart TD A[Atopic Dermatitis Diagnosis]:::outcome --> B{Severity?}:::decision B -->|Mild| C[Emollients + Topical CS]:::action B -->|Moderate| D[Emollients + Topical CS ± TCI]:::action B -->|Severe| E{Inadequate response?}:::decision E -->|No| F[Continue topical therapy]:::action E -->|Yes| G[Add systemic agent]:::action G --> H{Age & response?}:::decision H -->|≥6 months| I[Dupilumab preferred]:::action H -->|Acute flare| J[Short-term oral CS]:::action J --> K[Taper & transition to topical]:::action I --> L[Sustained remission with Th2 blockade]:::outcome ``` ### Treatment Hierarchy | Tier | Agent | Role | Limitation | |------|-------|------|------------| | **1st-line** | Emollients | Barrier repair, TEWL ↓ | Maintenance only | | **1st-line** | Topical CS (low–mid potency) | Anti-inflammatory | Facial atrophy risk | | **2nd-line** | Topical calcineurin inhibitors (TCI) | Steroid-sparing, safe on face | Expensive, black box warning (rare) | | **3rd-line** | Dupilumab | Biologic, Th2 blockade | Cost, injection, age ≥6 months | | **Avoid** | Systemic CS (maintenance) | Only acute exacerbations | Rebound, HPA suppression, dependence | **High-Yield:** The **correct first-line** for moderate AD is **topical corticosteroids + emollients**, NOT systemic corticosteroids. Systemic CS may be used for **short-term** control of acute flares (7–14 days) but are never maintenance therapy in AD. **Clinical Pearl:** Topical calcineurin inhibitors (tacrolimus 0.03–0.1%, pimecrolimus 1%) are particularly valuable for: - Facial involvement (avoid CS atrophy) - Intertriginous areas (maceration risk with CS) - Steroid-sparing in children **Mnemonic:** **STEP-AD** = Systemic (avoid), Topical (1st-line), Emollients (always), Phototherapy (resistant), Agents (biologic/TCI for severe) **Warning:** ~~Systemic corticosteroids as preferred first-line~~ — this is a **trap answer**. Systemic CS are associated with: - Rapid rebound flares on withdrawal - HPA axis suppression - Increased infection risk - Dependence and tachyphylaxis They are **only** for acute exacerbations, not maintenance.